TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05472285

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Verum
Description: After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).
Study: NCT05268731

Intervention type: PROCEDURE
Intervention: External plastic endoprosthesis
Description: Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external plastic endoprosthesis if the duodenum or jejunum cannot be accessed by a guide wire

Intervention type: PROCEDURE
Intervention: Combined external internal plastic endoprosthesis
Description: Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external/internal plastic endoprosthesis if the duodenum or jejunum can be accessed by a guide wire. No definitive drainage intended in initial procedure.

Intervention type: PROCEDURE
Intervention: Primary metal stent
Description: Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of a self-expanding metal stent if the duodenum or jejunum can be accessed by a guide wire. A definitive drainage is intended in the initial procedure, for example in patients with malign bile duct obstruction
Study: NCT06496906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: A regular closed tooth extraction was performed with the different devices from each arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: A regular closed tooth extraction was performed with the different devices from each arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: A regular closed tooth extraction was performed with the different devices from each arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Benex
Description: Benex was used to perform the intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physics Forceps
Description: Physics forceps were used to perform the intervention.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Extraction Forceps
Description: Conventional Extraction Forceps were used to perform the intervention.
Study: NCT06528353

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV16-E6 serology and HPV ctDNA
Description: In the event of a malignant lesion identified on clinical examination and/or imaging, treatment will be performed according to the standard of care. In the absence of any suspicious lesion, but in the event of HPV ctDNA positivity, prophylactic surgery of the tonsils and base of the tongue (the vast majority of HPV-related OPC develop in these regions) will be proposed to the patient, given the high risk of OPC. In case of refusal of this prophylactic surgery, close clinical and imaging monitoring will be performed.~Surgical specimens will be analyzed to confirm or not the presence of HPV-driven OPC and HPV ctDNA will be measured post-operatively to ensure disease clearance.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV16-E6 serology and HPV ctDNA
Description: In the event of a malignant lesion identified on clinical examination and/or imaging, treatment will be performed according to the standard of care. In the absence of any suspicious lesion, but in the event of HPV ctDNA positivity, prophylactic surgery of the tonsils and base of the tongue (the vast majority of HPV-related OPC develop in these regions) will be proposed to the patient, given the high risk of OPC. In case of refusal of this prophylactic surgery, close clinical and imaging monitoring will be performed.~Surgical specimens will be analyzed to confirm or not the presence of HPV-driven OPC and HPV ctDNA will be measured post-operatively to ensure disease clearance.
Study: NCT05672134

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iohexol measurement
Description: Invasive renal hemodynamic measurement of mGFR through the administration of Iohexol.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Iohexol measurement
Description: Invasive renal hemodynamic measurement of mGFR through the administration of Iohexol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geranylgeranylacetone (GGA)
Description: 13 weeks of treatment with GGA/placebo orally, followed by a wash-out period of 6 weeks, then reversal of the treatment arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Geranylgeranylacetone (GGA)
Description: 13 weeks of treatment with GGA/placebo orally, followed by a wash-out period of 6 weeks, then reversal of the treatment arms.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: The investigators will perform echocardiography to find changes in cardiac function.
Study: NCT06322472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Turkish Early Language Development Test (TEDIL)
Description: The Turkish Early Language Development Test (TEDIL) is a test that measures the receptive and expressive language skills of children between the ages of 2 and 7 years and 11 months.

Intervention type: OTHER
Group type: OTHER
Intervention: The Family Literacy Scale
Description: The Family Literacy Scale, which is a reliable and valid measurement scale, was developed by Kılıç, Doğan, and Özden (Kılıç, Doğan, and Özden 2017). The items of the scale consist of questions about parental literacy, child literacy, and early literacy. Parental Literacy Scale to identify and analyse situations such as the use of literacy skills, role modelling for children, performing simple literacy activities at home, on the street, etc. and generally helping children to learn to read and write.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Early Childhood Phonological Sensitivity Scale (PASECP)
Description: The Early Childhood Phonological Sensitivity Scale (PASECP), developed by Sarı and Aktan Acar (2013), measures the phonological awareness of children aged 60-72 months (Sari and Aktan Acar 2013).

Intervention type: OTHER
Group type: OTHER
Intervention: The Early Literacy Home Environment Scale (ELHES)
Description: The Early Literacy Home Environment Scale (ELHES) developed by Karaahmetoğlu and Turan is a reliable and valid questionnaire for assessing the early literacy home environment of families with children aged 0-6 years (Karaahmetoğlu and Turan 2020)

Intervention type: OTHER
Group type: OTHER
Intervention: Demographic Questionaries
Description: The demographic survey was prepared by the researchers. The demographic survey includes questions about educational status and family's socio-economic status.
Study: NCT06459687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab
Description: 6\~8 cycles of Socazolimab (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with Socazolimab (5 mg/kg), Q3w.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab
Description: 6\~8 cycles of placebo (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with placebo (5 mg/kg), Q3w.
Study: NCT06646198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Description: Perform transjugular intrahepatic portosystemic shunt under the guidance of DSA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: Half-dose donafenib, 100mg BID P.O. unless any evidence of disease progression or unacceptable side effects.
Study: NCT06198452

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vision Improvement
Description: Laser Vision Improvement for Patients with Age-Related Macular Degeneration
Study: NCT05672134

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Echocardiography
Description: The investigators will perform echocardiography to find changes in cardiac function.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minute walking distance test
Description: 6 minute walking distance test to compare exercise tolerance in participants.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: 6-minute walking distance test
Description: 6 minute walking distance test to compare exercise tolerance in participants.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EndoPAT
Description: Use of EndoPAT to measure endothelial function.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: EndoPAT
Description: Use of EndoPAT to measure endothelial function.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Para-amino Hippuric Acid test
Description: PAH-measurement to measure ERPF.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Para-amino Hippuric Acid test
Description: PAH-measurement to measure ERPF.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: 12-lead Electrocardiogram

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Electrocardiogram
Description: 12-lead Electrocardiogram
Study: NCT05943496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and/or aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and/or aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV
Study: NCT06055517

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pulsed low dose-rate radiotherapy (pLDRT)
Description: Radiation treatment will be carried out with high-energy photons (6MV) using intensity modulated radiation therapy (IMRT) or volumetric arc radiation therapy (VMAT). The daily dose is 2 Gy, divided into 10 subfractions of 0.2 Gy spaced by 3 minutes. The cumulative dose will be individualized for each patient and can range from a minimum of 40 Gy to a maximum of 60 Gy.
Study: NCT05500495

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04924400

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHIP Program
Description: GHP members randomized to the intervention arm will participate in the following activities:~* Attend 2 group meetings per week over 6 weeks, followed by one group meeting per week for 6 weeks (12 weeks total); each meeting will last about one hour. CHIP classes for weeks 1-4 and week 12 require in-person attendance, while week 5-11 classes can be attended either virtually or in-person.~* Receive a copy of The Optimal Diet, The Official CHIP Cookbook.~The following data will be collected at weeks 1,12 and 26:~* Biometrics: weight, BMI, waist circumference, systolic and diastolic blood pressure~* Biomarkers (blood tests): HbA1c, LDL-C~* Psychometrics: Wellbeing360 survey

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: GHP members assigned to the control arm will receive the routine standard of care for GHP members. Members will receive a summary of diabetes-related benefits available to members with type 2 diabetes.~The following data will be collected at weeks 1,12 and 26:~* Biometrics: Weight, BMI, waist circumference, systolic and diastolic blood pressure~* Biomarkers (blood tests): HbA1c, LDL-C~* Psychometrics: Wellbeing360 survey
Study: NCT05642897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind
Description: ACT, mindfulness, and compassion-based intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Group
Description: This intervention promotes the sharing of cancer-related experiences, active listening and a sense of community between participants.
Study: NCT06575127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI Protocol
Description: as mentioned in Arm description
Study: NCT06576518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: An individualised incremental exercise programme was simultaneously supported by an adherence plan to assess and promote compliance.
Study: NCT04898335

Intervention type: DEVICE
Intervention: Tendyne Mitral Valve System
Description: Tendyne Mitral Valve System for mitral valve disease in a commercial setting
Study: NCT05437380

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: peritumoral microbubbles and contrast-enhanced ultrasonography
Description: Inject 1ml microbubbles around the tumors. Then detect lymph vessel and lymph nodes under contrast-enhanced ultrasonography.
Study: NCT06048328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game Changers for Family Planning
Description: Game Changers for Family Planning (GC-FP) intervention. The intervention will consist of 6 group sessions. The sessions will focus on stigma reduction, disclosure decision making, knowledge, and building skills for advocacy. The 2-hour, weekly sessions will be facilitated by 2 trained peers who are MC users, and conducted in Luganda using a structured manual, and group format to facilitate: sharing of experiences to build support, modeling and motivation; group problem solving and role playing to build skills and self-efficacy; and homework between sessions to practice skills and generate experiences to be processed in the group.
Study: NCT05864794

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI scan of the brain
Study: NCT05986071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: • Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant
Study: NCT05202691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1 (Physical Therapy+Magnetic Field Therapy)
Description: A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain) adding a Magnetic Field Therapy using the Zimmer EmfieldPro device (Zimmer MedizinSysteme, Germany)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 (Physical Therapy)
Description: A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain)
Study: NCT06219382

Intervention type: DEVICE
Intervention: Neurorehabilitation ecosystem
Description: Over a period of six weeks, the participants will integrate the NEST system into their daily routines, running parallel to their regular neurorehabilitation treatment.
Study: NCT05946642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-Pyrimethamine/Amodiaquine
Description: Co-blister packaging of sulfadoxine-pyrimethamine (SP) dispersible tablets administered on the first day and amodiaquine (AQ) dispersible tablets administered once daily for three days. The dose of SPAQ will be determined according to the child's age.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)
Description: DP will consist of tablets containing 320/40 mg and 160/20 mg piperaquine/dihydroartemisinin per tablet. A full course of DP should be administered in accordance with the manufacturer's instructions, once a day for 3 days, according to body weight. DP should be taken orally with water and without food. It will be given in association with Ivermectin.~Ivermectin (IVM) will be available as 3 mg or 6 mg tablets to be administered at the doses of 300- 400μg/kg/day for 3 days (to the nearest whole tablet). IVM should also be taken with water on an empty stomach.
Study: NCT06422611

Intervention type: DEVICE
Intervention: Impression methods
Description: Both digital and conventional impressions were taken from same patients

Intervention type: DEVICE
Intervention: Impression methods
Description: Both digital and conventional impressions were taken from same patients
Study: NCT04776174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound using the telerobotic Melody system
Description: The children will first have a telerobotic ultrasound abdominal, pulmonary or cardiac followed by a classical ultrasound.
Study: NCT05815719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin Alfa
Description: 150 micrograms per dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin Alfa
Description: Variable dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin Alfa Biosimilar
Description: Variable dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urinary Human follicle stimulating hormone
Description: Variable dose.
Study: NCT05499494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beautifil Flow Plus X F00 injectable composite
Description: bioactive injectable composite

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tetric N ceram resin composite
Description: Nano hybrid resin composite
Study: NCT05950724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept Injection [Enbrel]
Description: 25 mg subcutaneous injection
Study: NCT04981587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength exercise
Description: Strength exercise protocol for upper and lower limbs, using weights and elastic bands

Intervention type: OTHER
Group type: OTHER
Intervention: Usual treatment
Description: The usual treatment is based on activities to enhance brain functions: attention, memory, executive functions, language and orientation.
Study: NCT06030999

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study product A (Wonderlab wonder4shape)
Description: Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study product B (Wonderlab wonder4shape)
Description: Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Study product C (placebo)
Description: Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
Study: NCT06536842

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Drain Placement
Description: These drains will be placed with the intention to decrease the incidence of postoperative hematoma

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Postoperative Drain Placement
Description: Participant will undergo lumbar spine fusion surgery and will not receive a postoperative drain
Study: NCT06574659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation breathing test guiding sequential invasive Ventilation and noninvasive ventilation weaing protocol
Description: Noninvasive ventilation breathing test guiding sequential invasive Ventilation and noninvasive ventilation weaing protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The standard SBT guiding weaning group
Description: The standard SBT guiding weaning protocol
Study: NCT04981587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual treatment
Description: The usual treatment is based on activities to enhance brain functions: attention, memory, executive functions, language and orientation.
Study: NCT05073016

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuromodulation
Description: neuromodulation: Neuromodulation is technology that acts directly upon nerves. It is the alteration-or modulation-of nerve activity by delivering electrical or magnetic stimulus/current.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motor learning training
Description: motor learning training requires performing a sequential training called finger taping task
Study: NCT06537518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone injection
Description: Dexamethasone, a potent glucocorticoid, decreases the inflammatory response, tissue damage, and pain after surgical procedures; which can be injected locally or Intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone injection
Description: Dexamethasone, a potent glucocorticoid, decreases the inflammatory response, tissue damage, and pain after surgical procedures; which can be injected locally or Intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.375% Injectable Solution
Description: Isobaric bupivacaine (0.375%) is injected into the adductor canal deeply to the sartorius muscle around the saphenous nerve after ensuring negative aspiration space.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.375% Injectable Solution
Description: Isobaric bupivacaine (0.375%) is injected into the adductor canal deeply to the sartorius muscle around the saphenous nerve after ensuring negative aspiration space.